[Final evaluation of the randomized multicenter study SAKK 40/81: adjuvant portal chemotherapy of curatively resected colorectal cancer].
Between 1981 and 1987, 533 patients from 9 institutions have been entered in a randomized trial to assess the value of adjuvant portal infusion (5-Fluorouracil, Mitomycin C) compared to radical surgery alone. Analysis of 469 evaluable patients at a median follow-up of 5.8 years revealed 110 recurrences in the control and 94 recurrences in the infusion group. Estimated 5-year disease-free survival was 52% and 61% respectively (hazard ratio 1:0.75; 95% confidence interval 0.57-0.99; p = 0.046). Overall survival was 59% in the control and 69 in the infusion group (p = 0.048). Adjuvant portal infusion did not influence the occurrence of liver metastases but reduced the overall recurrence rate.
Laffer
U
U
Departement Chirurgie der Universität, Kantonsspital, Basel.
Metzger
U
U
Aeberhard
P
P
Arigoni
M
M
Arma
S
S
Barras
J
J
Egeli
R
R
Martinoli
S
S
Müller
W
W
Schweizer
W
W
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D016685:Mitomycin / Q000008:administration & dosage; D011169:Portal Vein; D015996:Survival Rate
D016685:Mitomycin; D005472:Fluorouracil
Endauswertung der randomisierten Multizenter-Studie SAKK 40/81: Adjuvante portale Chemotherapie beim kurativ resezierten kolorektalen Karzinom.